Partnering
A robust growth strategy is important for a fast developing specialty biopharmaceutical company. Through strategic in-licensing and productive academic collaborations, ObsEva is building a portfolio of products and product candidates for women’s reproductive health that can address significant unmet medical needs for millions of women worldwide.
At ObsEva, our growth strategy includes the acquisition of additional novel clinical-stage assets that can address unmet needs for our patients. Clinical-stage assets of interest for ObsEva would meet the following criteria:
In July 2021, Obseva licensed the exclusive worldwide rights to develop, manufacturing and commercial rights to ebopiprant (OBE022) to Organon, a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with its headquarters located in Jersey City, New Jersey. Goldman Sachs acted as exclusive financial advisor to ObsEva
In November 2022, Xoma acquired the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA ,Darmstadt, Germany license Under the terms of the agreement, ObsEva is entitled to receive up to $113 million in upfront and milestone payments including $15 million which was paid at signing.
Should you represent a pharmaceutical company seeking a strong and committed partner for the development and the commercialization of a potential product, please do not hesitate to send an email to the contact below briefly describing your project.